Skip to main content
. 2012 Feb 3;14(10):1203–1214. doi: 10.1093/neuonc/nor223

Fig. 2.

Fig. 2.

Imaging changes associated with a vascular event in a patient treated with bevacizumab. A, Pretreatment. B, Ten months later. Rapid onset of weakness. Bevacizumab stopped. C,Twelve months later, 2 months after stopping bevacizumab. D, Fifteen months, 5 months after stopping bevacizumab. E, Twenty-one months after stopping bevacizumab.